Drugmaker Eli Lilly and Co said on Monday it would buy AurKa Pharma Inc to get access to the privately-held company’s experimental cancer treatment for solid tumors.
AurKa Pharma shareholders will get an upfront payment of $110 million and will be eligible to receive up to $465 million in regulatory and sales milestones, Eli Lilly said in a statement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.